You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Mifamurtide for the treatment of osteosarcoma

  • Technology appraisal guidance
  • Reference number: TA235
  • Published:  26 October 2011
  • Guidance
  • Tools and resources
  • Information for the public
  • History

Research recommendations coming out of this guidance

  • Further studies on the clinical effectiveness of mifamurtide when combined with the chemotherapy typical of UK clinical practice would be useful to determine the size of the effect of mifamurtide.

  • Further collection of quality of life data from people who are cured and who have experience of amputation and chemotherapy are also needed. Additional data on the health effects on parents, siblings and others with life-threatening illness would also be of value.

Back to top